281 related articles for article (PubMed ID: 26350436)
1. Mineral (Mal)Adaptation to Kidney Disease--Young Investigator Award Address: American Society of Nephrology Kidney Week 2014.
Wolf M
Clin J Am Soc Nephrol; 2015 Oct; 10(10):1875-85. PubMed ID: 26350436
[TBL] [Abstract][Full Text] [Related]
2. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 23: associations with cardiovascular disease and mortality in chronic kidney disease.
Negri AL
Int Urol Nephrol; 2014 Jan; 46(1):9-17. PubMed ID: 23296792
[TBL] [Abstract][Full Text] [Related]
4. The roles of the skeleton and phosphorus in the CKD mineral bone disorder.
Hruska KA; Mathew S
Adv Chronic Kidney Dis; 2011 Mar; 18(2):98-104. PubMed ID: 21406294
[TBL] [Abstract][Full Text] [Related]
5. Relationship between Fibroblast Growth Factor 23 and Biochemical and Bone Histomorphometric Alterations in a Chronic Kidney Disease Rat Model Undergoing Parathyroidectomy.
Liao HW; Hung PH; Hsiao CY; Liou HH; Lin HS; Huang TH; Jou IM; Tsai KJ
PLoS One; 2015; 10(7):e0133278. PubMed ID: 26186634
[TBL] [Abstract][Full Text] [Related]
6. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
7. FGF-23: the rise of a novel cardiovascular risk marker in CKD.
Heine GH; Seiler S; Fliser D
Nephrol Dial Transplant; 2012 Aug; 27(8):3072-81. PubMed ID: 22851630
[TBL] [Abstract][Full Text] [Related]
8. Serum fibroblast growth factor 23 (FGF-23): associations with hyperphosphatemia and clinical staging of feline chronic kidney disease.
Lin J; Lin L; Chen S; Yu L; Chen S; Xia Z
J Vet Diagn Invest; 2021 Mar; 33(2):288-293. PubMed ID: 33543676
[TBL] [Abstract][Full Text] [Related]
9. Phosphate Toxicity in CKD: The Killer among Us.
Ritter CS; Slatopolsky E
Clin J Am Soc Nephrol; 2016 Jun; 11(6):1088-1100. PubMed ID: 26912542
[TBL] [Abstract][Full Text] [Related]
10. The role of fibroblast growth factor 23 in chronic kidney disease-mineral and bone disorder.
Diniz H; Frazão JM
Nefrologia; 2013 Nov; 33(6):835-44. PubMed ID: 24158124
[TBL] [Abstract][Full Text] [Related]
11. Osteo-renal regulation of systemic phosphate metabolism.
Razzaque MS
IUBMB Life; 2011 Apr; 63(4):240-7. PubMed ID: 21438115
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota; an overlooked effect of phosphate binders.
Rahbar Saadat Y; Niknafs B; Hosseiniyan Khatibi SM; Ardalan M; Majdi H; Bahmanpoor Z; Abediazar S; Zununi Vahed S
Eur J Pharmacol; 2020 Feb; 868():172892. PubMed ID: 31870830
[TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease.
Manghat P; Fraser WD; Wierzbicki AS; Fogelman I; Goldsmith DJ; Hampson G
Osteoporos Int; 2010 Nov; 21(11):1853-61. PubMed ID: 20012018
[TBL] [Abstract][Full Text] [Related]
14. FGF-23 in children with CKD: a new player in the development of CKD-mineral and bone disorder.
Siomou E; Stefanidis CJ
Nephrol Dial Transplant; 2012 Dec; 27(12):4259-62. PubMed ID: 22848110
[TBL] [Abstract][Full Text] [Related]
15. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease.
Isakova T; Wahl P; Vargas GS; Gutiérrez OM; Scialla J; Xie H; Appleby D; Nessel L; Bellovich K; Chen J; Hamm L; Gadegbeku C; Horwitz E; Townsend RR; Anderson CA; Lash JP; Hsu CY; Leonard MB; Wolf M
Kidney Int; 2011 Jun; 79(12):1370-8. PubMed ID: 21389978
[TBL] [Abstract][Full Text] [Related]
16. Assessment of tubular reabsorption of phosphate as a surrogate marker for phosphate regulation in chronic kidney disease.
Hong YA; Lim JH; Kim MY; Kim Y; Yang KS; Chung BH; Chung S; Choi BS; Yang CW; Kim YS; Chang YS; Park CW
Clin Exp Nephrol; 2015 Apr; 19(2):208-15. PubMed ID: 24682550
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Toussaint ND; Pedagogos E; Lioufas NM; Elder GJ; Pascoe EM; Badve SV; Valks A; Block GA; Boudville N; Cameron JD; Campbell KL; Chen SSM; Faull RJ; Holt SG; Jackson D; Jardine MJ; Johnson DW; Kerr PG; Lau KK; Hooi LS; Narayan O; Perkovic V; Polkinghorne KR; Pollock CA; Reidlinger D; Robison L; Smith ER; Walker RJ; Wang AYM; Hawley CM;
J Am Soc Nephrol; 2020 Nov; 31(11):2653-2666. PubMed ID: 32917784
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of Action and Clinical Attributes of Auryxia
Ganz T; Bino A; Salusky IB
Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Isakova T; Cai X; Lee J; Mehta R; Zhang X; Yang W; Nessel L; Anderson AH; Lo J; Porter A; Nunes JW; Negrea L; Hamm L; Horwitz E; Chen J; Scialla JJ; de Boer IH; Leonard MB; Feldman HI; Wolf M;
Am J Kidney Dis; 2020 Feb; 75(2):235-244. PubMed ID: 31668375
[TBL] [Abstract][Full Text] [Related]
20. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
